Overview

Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation

Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to determine the efficacy and safety of KPI-121 ophthalmic suspension compared to placebo in subjects who have undergone cataract surgery. The efficacy and safety of two different concentrations and two different dosing regimens of KPI-121 are also being assessed.
Phase:
Phase 3
Details
Lead Sponsor:
Kala Pharmaceuticals, Inc.
Treatments:
Loteprednol Etabonate